Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Feb;117(4):615–618. doi: 10.1111/j.1476-5381.1996.tb15235.x

Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.

E R Sailer 1, L R Subramanian 1, B Rall 1, R F Hoernlein 1, H P Ammon 1, H Safayhi 1
PMCID: PMC1909340  PMID: 8646405

Abstract

1. 5-Lipoxygenase (5-LOX) products from endogenous arachidonic acid in ionophore-stimulated peritoneal polymorphonuclear leukocytes (PMNL) and from exogenous substrate (20 microM) in 105,000 g supernatants were measured. 2. The effects of natural pentacyclic triterpenes and their derivatives on 5-LOX activity were compared with the inhibitory action of acetyl-11-keto-beta-boswellic acid (AKBA), which has been previously shown to inhibit the 5-LOX by a selective, enzyme-directed, non-redox and non-competitive mechanism. 3. The 5-LOX inhibitory potency of AKBA was only slightly diminished by deacetylation of the acetoxy group or reduction of the carboxyl function to alcohol in intact cells (IC50 = 1.5 vs. 3 and 4.5 microM, respectively) and in the cell-free system (8 vs. 20 and 45 microM). 4. beta-Boswellic acid (beta-BA), lacking the 11-keto function, inhibited 5-LOX only partially and incompletely, whereas the corresponding alcohol from beta-BA, as well as amyrin, acetyl-11-keto-amyrin, 11-keto-beta-boswellic acid methyl ester had no 5-LOX inhibitory activity up to 50 microM in either system. 5. beta-BA only partially prevented the AKBA-induced 5-LOX inhibition, whereas the non-inhibitory compounds, amyrin and acetyl-11-keto-amyrin, almost totally antagonized the AKBA effect and shifted the concentration-inhibition curve for the incomplete inhibitor beta-BA to the right. In contrast, the non-inhibitory 11-keto-beta-BA methyl ester exerted no antagonizing effect. 6. The results demonstrate that the pentacyclic triterpene ring system is crucial for binding to the highly selective effector site, whereas functional groups (especially the 11-keto function in addition to a hydrophilic group on C4 of ring A) are essential for 5-LOX inhibitory activity.

Full text

PDF
615

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammon H. P., Mack T., Singh G. B., Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med. 1991 Jun;57(3):203–207. doi: 10.1055/s-2006-960074. [DOI] [PubMed] [Google Scholar]
  2. Ford-Hutchinson A. W., Gresser M., Young R. N. 5-Lipoxygenase. Annu Rev Biochem. 1994;63:383–417. doi: 10.1146/annurev.bi.63.070194.002123. [DOI] [PubMed] [Google Scholar]
  3. Hagmann W., Denzlinger C., Keppler D. Production of peptide leukotrienes in endotoxin shock. FEBS Lett. 1985 Jan 28;180(2):309–313. doi: 10.1016/0014-5793(85)81092-9. [DOI] [PubMed] [Google Scholar]
  4. Hagmann W., Keppler D. Leukotriene antagonists prevent endotoxin lethality. Naturwissenschaften. 1982 Dec;69(12):594–595. doi: 10.1007/BF00396357. [DOI] [PubMed] [Google Scholar]
  5. McMillan R. M., Walker E. R. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci. 1992 Aug;13(8):323–330. doi: 10.1016/0165-6147(92)90100-k. [DOI] [PubMed] [Google Scholar]
  6. Safayhi H., Mack T., Ammon H. P. Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol. 1991 May 15;41(10):1536–1537. doi: 10.1016/0006-2952(91)90575-p. [DOI] [PubMed] [Google Scholar]
  7. Safayhi H., Mack T., Sabieraj J., Anazodo M. I., Subramanian L. R., Ammon H. P. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992 Jun;261(3):1143–1146. [PubMed] [Google Scholar]
  8. Safayhi H., Sailer E. R., Ammon H. P. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995 Jun;47(6):1212–1216. [PubMed] [Google Scholar]
  9. Safayhi H., Tiegs G., Wendel A. A novel biologically active seleno-organic compound--V. Inhibition by ebselen (PZ 51) of rat peritoneal neutrophil lipoxygenase. Biochem Pharmacol. 1985 Aug 1;34(15):2691–2694. doi: 10.1016/0006-2952(85)90569-6. [DOI] [PubMed] [Google Scholar]
  10. Wendel A., Tiegs G. A novel biologically active seleno-organic compound--VI. Protection by ebselen (PZ 51) against galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol. 1986 Jul 1;35(13):2115–2118. doi: 10.1016/0006-2952(86)90578-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES